Switching from a first to a second tumour necrosis factor (TNF) alpha antagonist in patients with juvenile idiopathic arthritis by Schmeling H, Horneff G

Treatment of systemic-onset juvenile arthritis with canakinumab by Peitz J, Horneff G

Get full text

Open label multicenter study of once weekly Etanercept 0.8 mg/kg in active polyarticular Juvenile idiopathic arthritis (JIA) by Horneff G, Minden K, Foeldvari I, Kuemmerle-Deschner J, Thon A, Girschick H, Huppertz HI

Phase III, multi-centre, randomised, double blind, Placebo-controlled study for treatment of juvenile ankylosing spondylitis (AS) with Adalimumab by Thon A, Tzaribacev N, Kuester R, Kuemmerle-Deschner K, Foeldvari I, Huppertz HI, Fitter S, Horneff G, Borte M, Ganser G, Trauzeddel R, Minden K

Reduction in missed school days and improvement in parent activity participation in children with juvenile idiopathic arthritis treated with abatacept by Ruperto N, Lovell DJ, Li T, Paz E, Horneff G, Huppertz HI, Deslandre CJ, Minden K, Punaro M, Nunez AF, Sigal L, Block A, Covucci A, Martini A, Giannini EH

Efficacy and safety of canakinumab, a long acting fully human anti-Interleukin-1β antibody, in systemic juvenile idiopathic arthritis with active systemic features: results from a... by McCann L, Ozdogan H, Rutkowska-Sak L, Ferrandiz MA, Wulffraat NM, Brik R, Kallinich T, Erguven M, Berkun Y, Constantin T, Quartier P, Horneff G, Brunner H, Ruperto N, Lheritier K, Preiss R, Tseng L, Martini A, Lovell DJ

Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (SJIA): tender 52-week data by Espada G, Pardeo M, Chaitow J, Brown D, Allen R, Zulian F, Zuber Z, Wulffraat N, Joos R, Dolezalova P, Burgos-Vargas R, Woo P, Schneider R, Ruperto N, Brunner H, De Benedetti F, Flato B, Gerloni V, Horneff G, Wright S, Kenwright A, Lovell D, Martini A